Extending adjuvant dabrafenib + trametinib beyond one year linked to better relapse-free survival

Clefting identified in 40 percent of melanomas and 6 percent of benign lesions

Recurrence-free survival for second course of adjuvant treatment is lower with PD-1 checkpoint inhibitors versus BRAF + MEK inhibitors

Flare severity, duration, and number were among most important predictors of AD severity

NLR level >4.8 associated with increased risk for melanoma-specific death and developing distant metastases

Significant sex interaction observed, with stronger associations in the female group

Association between AD and increased risk for chronic kidney disease seen for men and women and in all age groups

Those with moderate-to-severe versus mild AA had 78 percent higher risk for being diagnosed with atopic dermatitis

Excellent interrater intraclass correlation coefficients seen for individuals with Fitzpatrick I to III, IV to VI skin types

Significantly higher hazard ratios seen for NAM than de novo melanoma for high nevus density, high genetic propensity for melanoma development

Differences between adalimumab and other targeted treatments mainly not significant

Probable associations seen for secondhand smoking exposure and traffic and industrial plant exposure with increased prevalence of atopic dermatitis

Female patients perceive that clinicians are significantly worse at demonstrating respect, listening, and explaining concepts

Key Takeaways

• Dozens of people in England got botulism after Botox procedures
• Botulism can be life-threatening
• Officials are also looking into illegal sales of...

The monoclonal antibody is a self-administered injection for prophylactic use to prevent attacks

Significant improvement seen in total-Vitiligo Area Scoring Index from baseline at week 24 for povorcitinib versus placebo

One-time surgical application of prademagene zamikeracel improves wound healing and pain

Benefits include sustained disease remission, reductions in itch, lower oral corticosteroids dose

Dupixent is the first and only FDA-approved treatment for bullous pemphigoid, demonstrating significant itch and blister reduction in clinical trials

Patients belonging to haplogroup T exhibit unique nivolumab-resistant baseline peripheral CD8+ T-cell repertoire

PanDerm was evaluated on a wide range of clinical tasks and trained on multiple image types

Three-year cumulative psoriasis incidence higher for those receiving dupilumab versus other systemic agents

Artificial intelligence-derived risk score prognostication system demonstrated superior sensitivity across all outcomes